Neumora Therapeutics (NASDAQ:NMRA – Get Free Report) and Vericel (NASDAQ:VCEL – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, profitability and earnings.
Analyst Ratings
This is a breakdown of recent ratings and target prices for Neumora Therapeutics and Vericel, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Neumora Therapeutics | 1 | 5 | 3 | 0 | 2.22 |
| Vericel | 0 | 0 | 7 | 0 | 3.00 |
Neumora Therapeutics currently has a consensus price target of $9.29, indicating a potential upside of 869.28%. Vericel has a consensus price target of $62.29, indicating a potential upside of 40.84%. Given Neumora Therapeutics’ higher probable upside, analysts clearly believe Neumora Therapeutics is more favorable than Vericel.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Neumora Therapeutics | N/A | N/A | -$235.93 million | ($1.53) | -0.63 |
| Vericel | $237.22 million | 9.35 | -$3.18 million | $0.18 | 245.69 |
Vericel has higher revenue and earnings than Neumora Therapeutics. Neumora Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Neumora Therapeutics has a beta of 2.59, indicating that its share price is 159% more volatile than the S&P 500. Comparatively, Vericel has a beta of 1.78, indicating that its share price is 78% more volatile than the S&P 500.
Institutional and Insider Ownership
47.7% of Neumora Therapeutics shares are owned by institutional investors. 26.4% of Neumora Therapeutics shares are owned by insiders. Comparatively, 5.2% of Vericel shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Neumora Therapeutics and Vericel’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Neumora Therapeutics | N/A | -73.63% | -68.97% |
| Vericel | 1.56% | 1.48% | 0.96% |
Summary
Vericel beats Neumora Therapeutics on 9 of the 13 factors compared between the two stocks.
About Neumora Therapeutics
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson’s disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
About Vericel
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Neumora Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neumora Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
